

GALI 1647

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: EISENBACH-SCHWARTZ et al

Art Unit: 1647

Application No.: 09/218,277

Examiner: S. Turner

Filed: December 22, 1998

Washington, D.C.

For: T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES

Atty.'s Docket: EIS-SCHWARTS=1A

Date: March 5, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Sir:

Transmitted herewith is an ☒ Amendment ☒ Two journal articles by Hauben et al  
in the above-identified application.☒ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.☒ No additional fee is required.☐ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 17	MINUS	** 20	0
INDEP.	* 1	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL

## SMALL ENTITY

	RATE	ADDITIONAL FEE
x	9	\$
x	40	\$
+	135	\$
ADDITIONAL FEE TOTAL		\$

## OTHER THAN SMALL ENTITY

	RATE	ADDITIONAL FEE
x	18	\$
x	80	\$
+	270	\$
TOTAL		\$

OR

OR

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

## Small Entity

## Response Filed Within

- ☐ First - \$ 55.00  
☐ Second - \$ 195.00  
☐ Third - \$ 445.00  
☐ Fourth - \$ 695.00

Month After Time Period Set

## Other Than Small Entity

## Response Filed Within

- ☐ First - \$ 110.00  
☐ Second - \$ 390.00  
☐ Third - \$ 890.00  
☐ Fourth - \$ 1390.00

Month After Time Period Set

☐ Less fees (\$ ) already paid for month(s) extension of time on .☐ Please charge my Deposit Account No. 02-4035 in the amount of \$ .☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ .☐ A check in the amount of \$ is attached (check no. ).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:   
 Roger L. Browdy  
 Registration No. 25,618

Facsimile: (202) 737-3528  
 Telephone: (202) 628-5197



#16/C  
32  
3-8-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EIS-SCHWARTZ=1A

In re Application of:	)	Art Unit: 1647
EISENBACH-SCHWARTZ et al	)	Examiner: S. Turner
Appln. No.: 09/218,277	)	Washington, D.C.
Filed: December 22, 1998	)	March 5, 2001
For: T-CELLS, NERVOUS SYSTEM- SPECIFIC ANTIGENS AND THEIR USES	)	

RECEIVED  
MAR 06 2001  
TECH CENTER 1600/2900

AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action of December 5,  
2000, please amend as follows:

IN THE CLAIMS

Replace original claims 3, 4, 5 and 16 with new  
claims 3, 4, 5 and 16 as follows:

3 (Twice-Amended). A method in accordance with  
claim 16, wherein said method is for ameliorating the effects  
of an injury selected from the group consisting of blunt  
trauma, penetrating trauma, hemorrhagic stroke, ischemic  
stroke, and damages caused by surgery, and wherein said human  
is one having said injury.

Sub  
C<sub>1</sub>